Journal of diabetes and its complications最新文献

{"title":"Adherence to statins and development of atherosclerosis-related events. A systematic review and meta-analysis","authors":"Athanasios Basios ,&nbsp;Christina A. Chatzi ,&nbsp;Georgios Markozannes ,&nbsp;Evangelia E. Ntzani ,&nbsp;Fotios Barkas ,&nbsp;Konstantinos K. Tsilidis ,&nbsp;Manfredi Rizzo ,&nbsp;Aikaterini Kalampoki ,&nbsp;Evangelos C. Rizos","doi":"10.1016/j.jdiacomp.2025.109040","DOIUrl":"10.1016/j.jdiacomp.2025.109040","url":null,"abstract":"<div><h3>Background</h3><div>Adherence to lipid-lowering treatment (LLT) is of paramount importance for the prevention of atherosclerosis-related events (ASCVD). The threshold for someone to be adherent is ≥80 % of the total prescribed medication. We conducted a meta-analysis to assess how adherence to LLT affects the development of ASCVD.</div></div><div><h3>Methods</h3><div>We searched PubMed (up to February 2025) for randomized controlled trials, cohorts and nested case control studies that assessed adherence to LLT. We performed random effects meta-analysis with primary outcome the development of ASCVD based on the level of adherence to LLT.</div></div><div><h3>Results</h3><div>We included 66 articles corresponding to 3,345,718 individuals. All studies evaluated statins as LLT. Good vs. poor statin adherence reduced by 35 % the risk for all-cause mortality (RR:0.65; 95%CI: 0.56–0.76; I² = 98 %), 24 % for any cardiovascular (CV) event (RR:0.76; 95%CI: 0.72–0.80; I² = 90 %), 30 % for myocardial infarction (MI) (RR:0.70; 95%CI: 0.62–0.80; I² = 90 %) and 32 % for stroke (RR:0.68; 95%CI: 0.58–0.79; I² = 81 %). For participants without established ASCVD, statin adherence reduced by 32 % the risk for any CV event (RR:0.68; 95%CI: 0.46–1.00; I² = 97 %). For those with established ASCVD, statin adherence reduced by 25 % the risk for any CV event (RR:0.75; 95%CI: 0.64–0.88; I² = 64 %), 51 % for MI (RR:0.49; 95%CI: 0.32–0.73; I² = 80 %) and 50 % for stroke (RR:0.50; 95%CI: 0.26–0.97; I² = 87 %). Statin discontinuation increased by 90 % the mortality risk (RR:1.90; 95%CI: 1.33–2.71; I² = 87 %). Even good vs. intermediate adherence (40 %–79 %) decreased by 32 % the risk for any CV event (RR:0.68; 95%CI: 0.60–0.76; I² = 94 %). Sensitivity analyses including studies with different than the standard (≥80 %) threshold did not differ from the main results.</div></div><div><h3>Conclusion</h3><div>Statin adherence is of paramount importance to reduce ASCVD risk and mortality. Understanding adherence patterns or barriers and ensuring consistent adherence to LLT by tailored interventions should be a key priority in clinical practice and healthcare policies.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 8","pages":"Article 109040"},"PeriodicalIF":2.9,"publicationDate":"2025-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144099307","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Response to rebuttal","authors":"Bria George","doi":"10.1016/j.jdiacomp.2025.109036","DOIUrl":"10.1016/j.jdiacomp.2025.109036","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109036"},"PeriodicalIF":2.9,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143879098","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Semaglutide, central retinal thickness and continuous glucose monitoring in persons with type 2 diabetes: A post-hoc analysis from a randomised trial","authors":"Søren Gullaksen ,&nbsp;Liv Vernstrøm ,&nbsp;Steffen Skovgaard Sørensen ,&nbsp;Kristian Løkke Funck ,&nbsp;Line Petersen ,&nbsp;Toke Bek ,&nbsp;Per Løgstrup Poulsen ,&nbsp;Esben Laugesen","doi":"10.1016/j.jdiacomp.2025.109039","DOIUrl":"10.1016/j.jdiacomp.2025.109039","url":null,"abstract":"<div><h3>Aims</h3><div>Glycemic control is important for preventing diabetic retinopathy (DR), but rapid improvements could deteriorate the disease. In some, but not all studies, semaglutide is speculated to worsen DR, but the mechanism is unknown. Central retinal thickness (CRT) is an early marker of DR. Therefore, the objective was to investigate whether increased Time in Range (TIR (3.9–10.0 mmol/L)), was associated with reduced CRT in persons treated with semaglutide.</div></div><div><h3>Methods</h3><div>Forty participants with type 2 diabetes were included in this post-hoc analysis of a 32-week randomised, placebo-controlled, partly open-label trial investigating the separate and combined effects of semaglutide and empagliflozin on target organ damage in 120 participants with type 2 diabetes. Individuals were randomised into four groups: i) semaglutide, ii) empagliflozin, iii) the combination or iv) placebo, <em>n</em> = 30 for each group). In the present study, 10 participants from each of the 4 arms participated. TIR was assessed using Continuous Glucose Measurement for 7–8 days and CRT was assessed using ocular coherence tomography.</div></div><div><h3>Results</h3><div>In the 10 individuals treated with semaglutide, CRT increased ~1 % (3.76 μm, 95%CI [−0.32; 7.85], <em>p</em> = 0.065) compared to placebo. This was attenuated with adjustment for TIR (<em>p</em> = 0.21).</div><div>Independently of the four interventions, increased TIR remained associated with increased CRT (0.07 μm, 95%CI[0.03; 0.12]μm, <em>p</em> = 0.002).</div></div><div><h3>Conclusion</h3><div>Semaglutide treatment did not impact CRT beyond what could be explained by changes in glycaemia. Across all interventions, increased TIR was associated with increases in CRT, thus supporting the link between rapid improved glycemia and DR.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109039"},"PeriodicalIF":2.9,"publicationDate":"2025-04-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Contents/Barcode","authors":"","doi":"10.1016/S1056-8727(25)00080-7","DOIUrl":"10.1016/S1056-8727(25)00080-7","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 5","pages":"Article 109027"},"PeriodicalIF":2.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143791470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A retrospective study to investigate the risk factors for gestational diabetes mellitus and its impact on maternal and neonatal outcomes","authors":"Xiujuan Zhang ,&nbsp;Yonghui Wang ,&nbsp;Huirong Zhao ,&nbsp;Shenglin Chen ,&nbsp;Xia Gao","doi":"10.1016/j.jdiacomp.2025.109035","DOIUrl":"10.1016/j.jdiacomp.2025.109035","url":null,"abstract":"<div><h3>Background</h3><div>Currently, risk factors for gestational diabetes mellitus (GDM) and its impact on maternal and neonatal outcomes have not been fully elucidated. Therefore, we performed a retrospective epidemiologic study to explore the above research objectives.</div></div><div><h3>Methods</h3><div>We collected extensive clinical data from January 2020 to June 2023 for 855 maternity cases at the Department of Obstetrics and Gynecology, Chaoyang Hospital, Capital Medical University. Vitamin D deficiency, undergoing assisted reproductive techniques, advanced maternal age (≥35), multiparas, abortion history, pre-pregnancy body mass index (≥25.0), twin pregnancy, polycystic ovary syndrome (PCOS), family history of diabetes, history of delivering a low-birth-weight infant, and weight gain during gestation of &gt;2 kg per month (mean) as variables that may affect GDM to investigate the risk factors for GDM. In addition, a total of 15 adverse postpartum outcomes (including maternal complications and neonatal complications) were used to explore the adverse effects of maternal comorbidity with GDM. Variables that were significant in the univariate logistic regression model were included in the multivariate logistic regression model. Receiver operating characteristic (ROC) curves were conducted for the ability to predict the risk of the GDM and its impact on maternal and neonatal outcomes, using variables derived from the multivariate logistic regression models.</div></div><div><h3>Results</h3><div>The results of multivariate logistic regression analyses shown that only multipara was not a risk factor for the development of GDM. Postpartum hemorrhage (blood loss ≥500 ml) and the neonatal Apgar score (≤9) (all <em>P</em> &gt; 0.05) was excluded in the multivariate logistic regression model. According to the results of multivariate logistic regression analyses, the incidence of hypothyroid complications, hyperlipidemic complications, postpartum anemia, gestational hypertension, racket placenta, premature rupture of membranes, fetal malposition, macrosomia (≥4000 g), low-birth-weight infants (&lt;2500 g), prematurity, neonatal infections, neonatal jaundice, and fetal distress was higher in pregnancies with combined GDM (all <em>P</em> &lt; 0.05). The model demonstrated excellent diagnostic performance, with an area under the ROC curve of 0.91, indicating its efficacy in predicting adverse prognostic outcomes associated with maternal GDM.</div></div><div><h3>Conclusions</h3><div>It is essential for women of childbearing age to correct vitamin D deficiency as well as to maintain their body mass index within the normal range before preparing for pregnancy. Maternal weight gain needs to be managed appropriately throughout pregnancy, which may reduce the risk of GDM to some extent. Therefore, our results suggest that effective measures to reduce the risk of GDM are essential for both the mother and the newborn.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109035"},"PeriodicalIF":2.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816651","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Postpartum diabetes mellitus among patients with early gestational diabetes: A systematic review and meta-analysis","authors":"Sarah J. Weingarten ,&nbsp;Ariel T. Levy ,&nbsp;Huda B. Al-Kouatly ,&nbsp;Rodney A. McLaren Jr.","doi":"10.1016/j.jdiacomp.2025.109038","DOIUrl":"10.1016/j.jdiacomp.2025.109038","url":null,"abstract":"<div><h3>Aims</h3><div>It is unclear whether patients diagnosed with early gestational diabetes mellitus (GDM) (&lt;24 weeks) are at higher risk of diabetes mellitus (DM) in the postpartum period compared to those with standard GDM (diagnosed ≥24 weeks). This study assessed if rate of DM diagnosed postpartum differs among patients with early versus standard GDM.</div></div><div><h3>Methods</h3><div>PubMed, EMBASE, WHO ICTRP, Clinicaltrials.gov and Cochrane Central Register of Controlled Trials were searched from inception to March 2023. Randomized controlled trials or observational studies that assessed rate of postpartum DM among patients with early GDM were included. Primary outcome was rate of DM diagnosed postpartum. Secondary outcomes were postpartum visit attendance, completion and results of postpartum oral glucose tolerance testing, and glycated hemoglobin (HbA1c) levels.</div></div><div><h3>Results</h3><div>Of 5682 studies screened, 11 met inclusion criteria (N = 1573 early GDM vs. N = 3340 standard GDM). Patients with early GDM had mean age of 30.2–37.0 years and mean body mass index (BMI) of 24.4–35.6 kg/m², while the standard group had a mean age of 28.9–32.8 years and mean BMI of 23.6–36.0 kg/m². Most studies evaluated postpartum glucose tolerance at 5–12 weeks, though one followed patients up to six years postpartum. Overall, patients with early GDM were more likely to be diagnosed with DM postpartum than those with standard GDM (12.8 % vs. 6.1 %, RR 1.89, 95 % CI 1.10–3.24). Impaired glucose tolerance was also higher in patients with early GDM (24.7 % vs. 13.0 %, RR 1.84, 95 % CI 1.32–2.57).</div></div><div><h3>Conclusions</h3><div>Rate of DM diagnosed postpartum was higher in patients with early GDM compared to standard GDM.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109038"},"PeriodicalIF":2.9,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143829424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comments on the article “the association between age at diagnosis of diabetes and development of diabetic retinopathy and assessment of healthcare access as an effect modifier “","authors":"Víctor Manuel Asensio-Sánchez","doi":"10.1016/j.jdiacomp.2025.108948","DOIUrl":"10.1016/j.jdiacomp.2025.108948","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 108948"},"PeriodicalIF":2.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143816650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Growth differentiation factor-15: A marker for diabetic kidney disease in patients with metabolic-associated fatty liver disease","authors":"Hassan A. Shora ,&nbsp;Ibrahim M. EL-Deen ,&nbsp;Naglaa M. El-Lithy ,&nbsp;Dina M. Abo-Elmatty ,&nbsp;Salma M. Khirallah","doi":"10.1016/j.jdiacomp.2025.109037","DOIUrl":"10.1016/j.jdiacomp.2025.109037","url":null,"abstract":"<div><h3>Background</h3><div>Growth/differentiation factor-15 (GDF-15) plays a crucial role in modulating inflammation and fibrosis and is emerging as a potential biomarker in metabolic diseases. This study investigated the association between circulating GDF-15 levels and the development of diabetic kidney disease (DKD) in patients with type 2 diabetes mellitus (T2DM), with or without metabolic dysfunction-associated fatty liver disease (MAFLD).</div></div><div><h3>Methods</h3><div>In this prospective observational study, participants were stratified into three groups: those with T2DM and MAFLD (Group A) and those with T2DM and no MAFLD (Group B), alongside a healthy control group (Group C). Comprehensive clinical evaluations and laboratory assessments, including measurements of GDF-15, metabolic profiles, liver enzymes, and renal function, were performed.</div></div><div><h3>Results</h3><div>GDF-15 levels demonstrated a stepwise elevation from controls to T2DM patients, with the highest levels observed in patients with MAFLD (1929 ± 412 pg/mL in Group A, 1655 ± 368 pg/mL in Group B, and 1246 ± 245 pg/mL in Group C; p &lt; 0.001). DKD was diagnosed in 51.4 % of patients in Group A compared to 37.1 % in Group B (p &lt; 0.001). Multivariate analysis identified GDF-15 as the sole independent predictor of DKD (p = 0.01). ROC curve analysis revealed that a GDF-15 cutoff value of ≥1890.51 pg/mL provided an AUC of 0.951, with a sensitivity of 94.2 % and specificity of 87.1 %.</div></div><div><h3>Conclusion</h3><div>Elevated GDF-15 levels are independently associated with an increased risk of DKD in T2DM patients, particularly in those with MAFLD. These findings highlight the potential of GDF-15 as an early biomarker for DKD.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109037"},"PeriodicalIF":2.9,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143826463","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Identifying predictors of sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 agonist use in hospital among adults with diabetes","authors":"Lai-Ming Kathleen Pak ,&nbsp;Minh V. Le ,&nbsp;Dev Kevat ,&nbsp;Rahul Barmanray","doi":"10.1016/j.jdiacomp.2025.109022","DOIUrl":"10.1016/j.jdiacomp.2025.109022","url":null,"abstract":"","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 10","pages":"Article 109022"},"PeriodicalIF":3.1,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144027384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Inflammation levels in type 2 diabetes mellitus patients with mild cognitive impairment: Assessment followed by amelioration via dapagliflozin therapy","authors":"Wei Zhang ,&nbsp;Chunping Sun ,&nbsp;Yating Huang ,&nbsp;Meng Zhang ,&nbsp;Ao Xu ,&nbsp;Chen Wang ,&nbsp;Fang Lv ,&nbsp;Tianrong Pan","doi":"10.1016/j.jdiacomp.2025.109017","DOIUrl":"10.1016/j.jdiacomp.2025.109017","url":null,"abstract":"<div><h3>Aims</h3><div>To investigate systemic inflammation and the effect of dapagliflozin treatment in (type 2 diabetes mellitus) T2DM patients with mild cognitive impairment (MCI).</div></div><div><h3>Methods</h3><div>Between January and December 2023, 200 participants were recruited from the Department of Endocrinology of Hefei First People's Hospital. Baseline data collected included medical history, fasting blood glucose, HbA1c, liver and kidney function, lipid profiles, IL-1β, TNF-α, sVCAM-1 level, and the urinary albumin-creatinine ratio (uACR). Based on their Montreal Cognitive Assessment Scale (MoCA) scores, these participants were categorized into two groups: 127 in the MCI group and 73 in the non-MCI group. MCI group received dapagliflozin (10 mg daily) alongside standard treatment.</div></div><div><h3>Results</h3><div>The MCI group showed higher age, height, weight, BMI, HbA1c, FBG, disease duration, carotid plaques, stenosis rates, and elevated IL-1β, TNF-α, and sVCAM-1. MoCA scores were significantly lower in the MCI group. Correlation analysis showed a negative correlation of MoCA scores with IL-1β, TNF-α, sVCAM-1, plaques, stenosis, FBG, and HbA1c, and a positive correlation with height. Binary logistic regression identified age, BMI, IL-1β, sVCAM-1, and FBG as predictors of cognitive impairment in T2DM. Dapagliflozin treatment reduced BMI, HbA1c, inflammatory markers, and FBG, improving MoCA scores.</div></div><div><h3>Conclusion</h3><div>Dapagliflozin treatment may improve cognitive function by reducing inflammation.</div></div>","PeriodicalId":15659,"journal":{"name":"Journal of diabetes and its complications","volume":"39 6","pages":"Article 109017"},"PeriodicalIF":2.9,"publicationDate":"2025-03-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143824090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}